If youre pressed for time, Hunter already made a 15-minute video summarizing his experience with injectable L-Carnitine: NOTE: This article will be much more to-the-point and less heavy on scientific references, but it will be updated in the near future with more esoteric intel and clinical research
As patient preference may potentially be influenced by recent media attention on GLP-1 RAs, communicating the importance of early kidney protection will be crucial to ensure informed shared decision-making
Deborah Levine: Nothing to disclose E-Posters - RECOVERY, REHABILITATION AND OUTCOME 03.00 - RECOVERY, REHABILITATION AND OUTCOME - 03.03 - PROGNOSIS AND OUTCOME AFTER STROKE P2225 - ESOC25-874 USE OF ANTIDEPRESSANTS IN YOUNG STROKE PATIENTS: INSIGHTS FROM A MULTICENTER STUDY Jenna Broman 1 , Daniela Pinter 2 , Simon Fandler-Hfler, Bettina von Sarnowski 3 , Mohamed Elmegiri 4 , Thomas Gattringer 5,6 , Robert Malinowski 3 , Juha Martola 4 , Stefan Ropele, Ulf Schminke 3 , Turgut Tatlisumak 1,7 , Christian Enzinger, Karoliina Aarnio 1 , Jukka Putaala 1 1 Department of Neurology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, 2 Department of Neurology, Research Unit for Neuronal Plasticity and Repair, Medical University of Graz, Graz, Austria, 3 Department of Neurology, University Medicine Greifswald, Greifswald, Germany, 4 Department of Radiology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, 5 Department of Neurology, Medical University of Graz, Graz, Austria, 6 Division of Neuroradiology, Vascular and Interventional Radiology, Department of Radiology, Medical University of Graz, Graz, Austria, 7 Department of Clinical Neuroscience, Institute of Neurosciences and Physiology, Sahlgrenska Academy at University of Gothenburg & Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden Background and Aims: Depression after stroke is common and occurs in approximately one-third of patients, potentially affecting their quality of life and worsening the outcome
(Thats possible to do, but its a somewhat annoying extra step.) Since youll already be paying $20 to $40 per year for Shotsy, this is a notable drawback
In parallel, we released a companion report that uses dispense data to examine switching patterns during the same period as the CVS formulary change, providing a complementary perspective on how patients transitioned between GLP-1 RAs
